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Abstract 
 
Objectives 
The limited positive predictive value of an incomplete response on PET-CT following 
(chemo)radiotherapy for head and neck squamous cell carcinoma (HNSCC) means that the optimal 
management strategy remains uncertain.  The aim of the study is to assess the utility of a ‘second-
look’ interval PET-CT. 
 
Methods 
Patients with HNSCC who were treated with (chemo)radiotherapy between 2008-17 and underwent 
i) baseline and ii) response assessment PET-CT iii) second-look PET-CT following incomplete (positive 
or equivocal scan) response were included.  Endpoints were conversion rate to complete response 
(CR) and test characteristics of the second-look PET-CT. 
  
Results 
562 patients with HNSCC underwent response assessment PET-CT at a median of 17 weeks post-
radiotherapy.  Following an incomplete response on PET-CT, 40 patients underwent a second-look 
PET-CT at a median of 13 weeks (range 6-25) from first response PET-CT.  34/40 (85%) patients had 
oropharyngeal carcinoma.  24/40 (60%) of second-look PET-CT scans converted to a complete 
locoregional response.  The primary tumour conversion rate was 15/27 (56%) and the lymph node 
conversion rate was 14/19 (74%).  The sensitivity, specificity, PPV and negative predictive value 
(NPV) of the second-look PET-CT for were 75%, 75%, 25% and 96% for the primary tumour, and 
100%, 92%, 40% and 100% for lymph nodes.  There were no cases of progression following 
conversion to CR in the primary site or lymph nodes. 
 
Conclusions 
The majority of patients who undergo a second-look PET-CT convert to a CR.  The NPV of a second-
look PET-CT is high, suggesting the potential to avoid surgical intervention. 
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Keypoints 
PET-CT is a useful tool for response assessment following (chemo)radiotherapy for head and 
neck squamous cell carcinoma 
 
An incomplete response on PET-CT has a limited positive predictive value and optimal 
management is uncertain. 
 
These data show that with a ‘second-look’ interval PET-CT the majority of patients convert 
to a complete metabolic response.   When there is doubt about clinical and radiological 
response a ‘second-look’ PET-CT can be used to spare patients unnecessary surgical 
intervention  
  
 
Abbreviations 
 
CR = complete response 
EUA = examination under anaesthetic 
FDG = 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose 
HNSCC = head and neck squamous cell carcinoma 
HPV = human papilloma virus 
IMRT = intensity modulated radiotherapy 
NPV = negative predictive value 
PET-CT = positron emission tomography -computed tomography 
PF = cisplatin and 5-fluorouracil 
PPV = positive predictive value 
TPF = docetaxel, cisplatin and 5-fluorouracil   
 
Introduction 
 
Accurate response assessment following (chemo)radiotherapy for head and neck squamous cell 
carcinoma (HNSCC) is required to select patients for clinical follow up from those who require 
surgical treatment.  The difficulty in determining the significance of residual masses post-treatment 
limits the utility of anatomical imaging with CT and/or MRI [1]. 2-[Fluorine-18]-fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography -computed tomography (PET-CT) combines anatomical 
and functional imaging. The recent randomised PET-NECK trial in HNSCC patients with nodal disease 
found a strategy of FDG PET-CT guided surveillance had non-inferior survival when compared with a 
planned neck dissection and was more cost effective [2]. Response assessment with FDG PET-CT 
following chemoradiotherapy is now a standard of care, in PET-CT imaging guidelines [3] and 
management guidelines [4; 5].   
 
The negative predictive values (NPV) of response assessment FDG PET-CT have been shown to be 
excellent, identifying patients who do not require surgical intervention [6-14].  This applies even in 
the context of metabolically inactive residual masses [8; 15].  However, PET-CT scans are susceptible 
to false positive results, with post-radiotherapy inflammation, reactive changes and physiological 
uptake [16].  This results in a limited positive predictive values (PPV). A PPV of 52% was reported in a 
meta-analysis [17], whilst individual series have shown lower PPVs [6; 7; 10; 11; 14; 18].  In the PET-
NECK trial patients with a partial or equivocal response underwent a neck dissection [2].  However, 
the limited PPV of response assessment FDG PET-CT suggests that a policy of intervention for all 
patients who do not achieve a complete response on PET-CT may represent overtreatment [14].   
 
The optimal strategy following a positive or equivocal PET-CT response scan remains uncertain.  
Increasing time from completion of treatment may allow post-radiotherapy inflammatory/reactive 
FDG-uptake to reduce.  This provides the rationale to repeat the PET-CT after a further interval.  One 
recent series [18] reported performing a second interval FDG PET-CT in 41 patients with human 
papilloma virus (HPV)-associated oropharyngeal carcinoma with a 71% conversion rate to complete 
response.   
 
In our centre FDG PET-CT has been used to assess response since 2008 and over time have adopted 
an approach of performing a ‘second-look’ PET-CT in patients with uncertainty regarding response.  
The aim of this report is to evaluate the accuracy and utility of a second-look FDG PET-CT. 
 
 
Methods 
 
The study involved retrospective analysis performed under a waiver of informed consent and ethics 
approval by the Institutional Review Board.  Consecutive patients who had a FDG PET-CT performed 
for response assessment after (chemo)radiotherapy for HNSCC between August 2008-May 2017 
were identified using an institutional database.  Inclusion criteria: i) squamous cell carcinoma of 
oropharynx, hypopharynx, larynx, oral cavity, paranasal sinuses or unknown primary site, ii) 
(chemo)radiotherapy with curative intent, iii) pre-treatment FDG PET-CT, iv) FDG PET-CT as first 
response assessment.  The subgroup of patients who had undergone a second-look FDG PET-CT 
performed following MDT discussion due to uncertainty regarding response status were identified 
for analysis.  There was no institutional policy on selection of patients for a second-look PET-CT and 
this decision was made on the discretion of the MDT and participating clinicians.  Patients were 
excluded from the analysis if they had undergone prior therapeutic resection. 
 
Staging 
Routine staging included nasoendoscopy, examination under anaesthetic (EUA) with biopsy if 
indicated, MRI and/or contrast-enhanced CT of neck, CT thorax.  A pre-treatment FDG PET-CT was 
done to optimally stage patients and provide a baseline for interpretation of subsequent response 
assessment for patients who had with bulky stage II or stage III/IV disease.  A specialist Head & Neck 
Multidisciplinary meeting routinely reviewed all imaging and assigned an American Joint Committee 
on Cancer TNM staging 7th edition classification [19].   
 
Radiotherapy 
A 3D-CT planned technique was utilised early in this period [20].  Intensity modulated radiotherapy 
(IMRT) was subsequently became standard [12; 21]. Institutional protocols were followed with daily 
fractionation schedules of 70Gy in 35 fractions or 65Gy in 30 fractions, with prophylactic doses of 54-
63 Gy in 30-35 fractions.    
 
Chemotherapy 
 
A proportion of patients received induction chemotherapy with either docetaxel/cisplatin/5-
fluorouracil (TPF) or cisplatin/5-fluorouracil (PF) [21]. Concurrent chemotherapy was using cisplatin 
100mg/m2 on days 1 and 29 or 1, 21 and 43.  
 
 
Response assessment  
Response was routinely assessed approximately 4 months post-treatment, and included clinical 
examination, naso-endoscopy if indicated and a FDG PET-CT. PET-CT scans were reviewed in MDT 
meetings were a consensus decision made regarding management for patients with less than a 
complete response.  
 
FDG PET-CT protocol 
FDG PET-CT scans were performed before June 2010 on a 16-slice Discovery STE PET-CT scanner (GE 
Healthcare), between June 2010-October 2014 on a 64-slice Philips Gemini TF64 scanner (Philips 
Healthcare), subsequent to October 2014 on a 64-slice Discovery 710 scanner (GE Healthcare). 
Patients were fasted for 6 hours prior to intravenous Fluorine-18 FDG injection.  Scanning was only 
carried out if blood glucose was < 10 mmol/L. Acquisition of PET was performed 60-minutes 
following tracer injection. Physiological tracer activity was minimised within the head and neck 
region using a silence protocol (no talking) during the uptake period following tracer injection [22; 
23]. The CT component of the scan was performed using a standard protocol (without iodinated 
contrast) with the following settings: 140 kV; 80 mAs; a tube rotation time of 0.5s per rotation; pitch 
6; section thickness 3.75 mm.  
Categorisation of FDG PET-CT response assessment 
PET-CT reports were used for the analysis to categorise the FDG PET-CT response.  FDG PET-CT scans 
were reported by experienced radiologists who were dual certified in Nuclear Medicine and 
Radiology.  FDG PET-CT images assessment was performed qualitatively by comparison of tumour or 
nodal tracer activity to background physiological uptake.  A semi-quantitative assessment using 
maximum standardised uptake value (SUVmax) of both residual tumour and/or nodal uptake was 
routinely documented. As previously described [6; 12], the first post-treatment FDG PET-CT were 
categorised into ‘positive’, ‘equivocal’ or ‘complete response’ (CR) for the primary site and lymph 
nodal sites separately.  Sites of FDG uptake were classified as positive if the uptake was focal and 
corresponded to an anatomical structural abnormality with greater intensity than that of 
background liver.  A scenario of focal uptake of greater intensity than background liver which does 
not correspond to a structural abnormality is not easy to define with the low dose non-contrast CT 
but would be commented upon by the PET-CT report for MDT discussion rather than classified as a 
positive scan.  Scans were classed as equivocal if focal FDG uptake had reduced from baseline 
 
imaging and was lower than liver background but higher than adjacent normal tissues.   Scans were 
classified as negative if there was no abnormal focal FDG uptake or only diffuse FDG uptake without 
a corresponding anatomical abnormality on the CT and was considered radiotherapy-related. This 
negative response classification includes cases with a residual mass with no abnormal FDG uptake, 
even if there was a possible increase in size of residuum.  PET-CT reports routinely included details of 
residual tissue even if metabolically inactive.  These details would be reviewed by the clinical 
team/MDT and management decisions made on an individual basis.  The same reporting approach 
was used for the second-look PET-CT.   
Analysis and statistics 
Duration of follow up was defined as being from final day of radiotherapy treatment.  The disease 
status was determined from any pathology and/or radiology reports and electronic notes review of 
outcomes.  2x2 tables constructed using clinicopathological outcomes were used to calculate 
sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV). 
 
 
 
Results 
 
562 patients were identified with HNSCC who had undergone a baseline and response assessment 
PET-CT following (chemo)radiotherapy.   Median time from end of radiotherapy to response 
assessment PET-CT was 17 weeks (range 6-31 weeks).  The median baseline tumour SUVmax and node 
SUVmax were 11.0 (range 0-53) and 8.1 (range 0-34) respectively. On the response PET-CT, 180/562 
(32%) had residual avidity at primary site, median SUVmax 5.7 (range 1.3-14.3).  140/562 (25%) had 
residual activity in regional lymph nodes with a median 3.2 (range 1-12.5).  Median follow-up period 
was 26 months (from completion of radiotherapy (range 3-148 months)). Overall 2-year local 
control, regional control, distant metastasis free rate, progression free survival and overall survival 
were 89%, 85%, 88%, 73% and 79% respectively.  40 patients underwent a second-look PET-CT.  Out 
of 522 did not have a second-look PET-CT, 147/522 had subsequent disease progression. Progression 
at the primary site occurred in 60/522, at regional lymph nodes in 80/522, and distant metastases in 
67/522.   This included 21 patients with progression at both the primary site and regional lymph 
nodes and 35/67 with distant metastases also having local and/or regional progression.  Of these 
522 patients, the sensitivity, specificity, PPV and NPV of the response assessment PET-CT for primary 
disease and lymph node disease was 79.5%, 88.8%, 57.9%, 95.7% and 71.3%, 93.1%, 68.7% and 
93.8% (equivocal and positive response categories combined for purposes of analysis). 
 
Group who underwent a second-look PET-CT (n=40) 
40/562 (7%) patients underwent a second-look PET-CT scan.  For each of these patients, disease 
status following the first response assessment PET-CT was considered by the clinical team to be 
uncertain.  Patient, disease and treatment details for the whole cohort and the subgroup who 
underwent a second-look PET-CT scan are shown in Table 1.  34/40 (85%) patients had 
oropharyngeal carcinoma, and 24/34 were p16 positive, 3/34 p16 negative and 7/34 unknown p16 
status.  In the group of 40 patients, the median values (range) of baseline tumour SUVmax and node 
SUVmax were 12.0 (range 0.7-53) and 9.4 (range 2.1-34) respectively.  Median time from completion 
of radiotherapy to first response assessment PET-CT was 16.8 weeks (range 12-20). Table 2 details 
the response categories (CR, equivocal or positive) on the first response assessment PET-CT with 
regard to primary site and nodes for these 40 patients.  All patients who underwent a second-look 
PET-CT had a metabolically equivocal or positive response category initial PET-CT ie. a second-look 
PET-CT was not utilised for patients with a metabolically inactive residual mass.  On the first 
response PET-CT, in patients with avidity at the primary site (n=27) median tumour SUVmax was 4.7 
(range 3.7-10.7).  24/27 of these patients had oropharyngeal carcinoma.  For patients with ongoing 
 
avidity within lymph nodes (n=19), median node SUVmax was 2.8 (range 1.6-7.1).  15/19 of these 
patients had oropharyngeal carcinoma. 
 
The second-look PET-CT was performed at a median of 13 weeks (range 6-25) after the first response 
assessment PET-CT.  Table 3 provides details of response categorisation for primary tumour and 
nodes on the second-look PET-CT (CR, equivocal, positive).  Overall 24/40 (60%) of second-look PET-
CT scans converted to a complete locoregional response.  The primary tumour conversion rate was 
15/27 (56%); all of these 15 patients had oropharyngeal carcinoma. An example is shown in Figure 
1A.  The median primary tumour SUVmax on the second-look PET-CT in the 12 patients not achieving 
a primary tumour CR was 4.6 (range 2.2-8.5).   The lymph node conversion rate was 14/19 (74%); 11 
of these 14 patients had oropharyngeal carcinoma.  An example is given in Figure 1B.  The median 
nodal SUVmax on the second-look PET-CT in the 5 patients not achieving a nodal CR was 2.4 (range 
1.5-3.8).  Overall in these 40 patients, 4 (10%) had confirmed residual primary tumour (one of these 
patients had a complete response at primary site on first response PET-CT and second-look PET-CT) 
and 2 (5%) had lymph node disease.    
 
Flow diagrams to illustrate outcomes of second-look PET-CT for patients with avidity at primary 
tumour site (n=27) and lymph nodes (n=19) on first response assessment PET-CT are shown in 
Figures 2A and 2B respectively. The 3 patients shown in Figure 2A who had persistent disease at the 
primary site had stable PET-CT findings on the second look PET-CT (one was unfit for salvage surgery, 
one unresectable  with a T4 posterior pharyngeal wall carcinoma at baseline and one developed lung 
metastases on the second-look PET-CT in addition to persistent local disease). The patient in Figure 
2B with an equivocal nodal response on the second-look PET-CT who suffered a regional recurrence 
on follow up had declined a neck dissection following this PET-CT.  Table 4 shows a breakdown of 
second-look PET-CT response categories (CR, equivocal and positive) by primary tumour and lymph 
node with disease outcome, providing PPV and NPV.  If equivocal and positive results are combined 
for analysis, the sensitivity, specificity, PPV and NPV of the second-look PET-CT for were 75%, 75%, 
25% and 96% for the primary tumour, and 100%, 92%, 40% and 100% for lymph nodes. 
 
Lung metastases were confirmed in 4/40 (10%) on the second-look PET-CT.  These patients had new 
non-avid sub-centimetre lung nodules with the differential considered to be inflammatory/infective 
changes or early metastases to small to characterise on free-breathing PET (n=3) or ‘inflammatory-
appearing’ lung changes (n=1) on the initial response assessment PET-CT in conjunction with 
locoregional avidity with clinical uncertainty over locoregional response.  
 
Discussion 
 
Response assessment FDG PET-CT is well-established following chemoradiotherapy with a high NPV 
at primary site and lymph nodes [7-11].  It has been shown to be possible to spare patients a neck 
dissection without compromising outcomes in the event of a complete response on PET-CT [2]. 
Although much of the focus has been in neck management, a high NPV also avoids the need for 
EUA/biopsy of the primary site.  The optimal timing of the response assessment PET-CT is uncertain 
and is a trade off between scan accuracy and allowing timely surgical intervention in the event of 
treatment failure.  Imaging early post-treatment is associated with false negative results as viable 
cancer cells may have insufficient time to repopulate post-treatment to be detectable by PET-CT; in 
addition, false positive scans are more likely due to post-radiotherapy inflammation [24].  One study 
demonstrated that scans <7 weeks post-treatment were less accurate than those performed later 
[25].  In a meta-analysis, PET scans >12 weeks post-treatment had a higher sensitivity [17].  Due to 
the lower NPV of earlier scans, response assessment at a minimum of 12 weeks post treatment is 
recommended [4; 5; 18].  A baseline PET is valuable in accurately reporting the response assessment 
PET-CT [26].  The approach in our centre is to  perform a baseline PET-CT and assess response 16 
weeks post-treatment; this has been associated with a high NPV [6; 12].  However, even when 
imaging at later, equivocal and positive scans are common with limited PPV [6-8; 14].  For example, 
in our prior report we found the PPV of equivocal nodal uptake was only 20% [6].  PPV is likely to be 
lower for HPV-related oropharyngeal carcinoma who have a more favourable prognosis and a lower 
pre-treatment probability of residual disease [18].   
 
The objective of this study was to evaluate the utility of a repeat, second-look FDG PET-CT in guiding 
management following an incomplete response on the initial PET-CT response scan (including 
positive and equivocal scans). Overall 60% of second-look PET-CT scans converted to a complete 
locoregional response.  The primary tumour conversion rate was 56% and the lymph node 
conversion rate was 74%.  Critically the NPV of the second-look PET-CT was very high (96% for 
primary site and 100% for lymph nodes).  These data demonstrate that many patients will have a 
complete response on a second-look PET-CT, avoiding the need for surgical intervention including 
biopsies, EUAs and neck dissections.  The only case of primary tumour failure following a complete 
primary tumour response on second-look PET-CT was a patient who had had the second-look PET-CT 
due to positive nodal uptake and had a complete response at the primary site on the initial response 
scan.  As shown in Figure 2 there were no recurrences at the primary tumour site or lymph nodes 
which converted from incomplete response to complete response on the second-look PET-CT.  With 
 
regard to lymph node uptake, FDG avidity remained stable on the second-look PET-CT in 5/19 
patients.  Two underwent a neck dissection with positive pathology in one.  The three remaining 
patients were clinically observed, including one with HPV-positive disease who declined a neck 
dissection and subsequently suffered regional recurrence.  Our current practice is to recommend a 
neck dissection if an equivocal or positive nodal scan fails to convert to a complete response on the 
second-look PET-CT.   
 
There is limited other data exploring the accuracy of a second-look PET-CT. Liu et al. [18] reported on 
a series of 41 patients with HPV-associated oropharyngeal carcinoma and an equivocal or partial 
nodal response on initial PET-CT 12 weeks post chemoradiotherapy.  A repeat PET-CT was performed 
after a further 16 weeks.  Similar to our experience, there was a 71% conversion rate to a complete 
response and a high NPV of 97%.  The authors recommended the use of repeat PET-CT to spare 
patients from unnecessary neck dissection.  Vainshtein et al. [7] also reported on patients with HPV-
related oropharyngeal carcinoma and serial surveillance. 21/22 (95%) and 12/12 (100%) of patients 
with an incomplete response at the primary site and nodes respectively on initial 3-month PET-CT 
assessment converted to a complete response on subsequent surveillance PET-CT.  
 
Limitations of this study include the selection of the patients for the second-look PET-CT. There was 
no institutional protocol to guide this decision and it was based upon the “real world” opinion of the 
MDT/treating clinicians based on imaging and clinical findings.   The rationale for the second-look 
PET-CT was uncertainty regarding response based upon clinical assessment and PET-CT.  All second-
look PET-CT scans were performed after an either equivocal or positive initial PET-CT based upon 
metabolic activity; this study does not inform on the value of repeated PET-CT in the context of a 
residual metabolically inactive residuum.  Comparison between PET-CT response studies is 
challenging due to the lack of consensus regarding the optimal ‘scoring’ system [24; 27; 28].  There is 
considerable variation in what can be considered to be a ‘positive’ scan with series using a stricter 
definition reporting higher PPVs [14].  In routine practice we have used a similar semi-quantitative 
approach to reporting PET-CT scans [8; 18].   The cases in our analysis are predominantly 
oropharyngeal carcinoma.  The value of a second-look PET-CT in non-oropharyngeal or HPV-negative 
oropharyngeal disease remains uncertain.   
 
In conclusion, our results suggest the majority of patients who undergo a second-look PET-CT will 
convert to a complete response.  This suggests that decisions regarding surgical intervention could 
be deferred until after the repeat scan, sparing many patients the need for intervention.   
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Figures 
 
Figure 1.  Examples of patients with incomplete response on response assessment FDG PET-CT with 
conversion to complete response on second-look PET-CT in primary site (A) and lymph node (B).  A). 
T3 N2c MO (TNM7) p16+ve base of tongue squamous cell carcinoma; SUVmax at baseline in primary 
site 13.1, response assessment 6.3 and complete response on second-look PET-CT.  B). T0 N2a M0 
(p16 unknown); SUVmax in necrotic lymph node at baseline 13.0, response assessment 3.1, 
complete response on second-look PET-CT (physiological uptake present in right masseter). 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Flow diagrams summarising A) Patients undergoing second-look FDG PET-CT with 
uncertain primary tumour response on initial response assessment PET-CT.  1B) Patients undergoing 
second-look PET-CT with uncertain lymph node response on initial response assessment PET-CT.  
 
 
 
Tables 
 
Table 1: Patient, disease and treatment details of patients who underwent response 
assessment PET-CT (n=562) and of the subgroup who underwent a second-look PET-CT scan 
(n=40). 
 
Characteristics  1st PET 
response 
(total 562) 
n (%) 
2nd -look PET 
response 
(total 40)  
n (%) 
Age  Median (range) 58 (24-84) 61 (45-76) 
Gender  Male 423 (75) 27 (68) 
Female 139 (25) 13 (32) 
Smoking Smoker 205 (36) 12 (30) 
Ex-smoker 176 (31) 13 (33) 
Never Smoked 149 (7) 14 (35) 
Not recorded 32 (6) 1 (3) 
Tumour site Paranasal Sinus 9 (2) 0 (0) 
Oral Cavity 7 (1) 0 (0) 
Oropharynx 397 (71) 34 (85) 
Hypopharynx 53 (9) 2 (5) 
Larynx 48 (9) 2 (5) 
Unknown 48 (9) 2 (5) 
Grade Well Differentiated 7 (1) 0 (0) 
Moderate 
Differentiated 
118 (21) 10 (25) 
Poorly 
Differentiated/ 
Basaloid 
364 (65) 24 (60) 
Undifferentiated 6 (1) 0 (0) 
Not recorded 67 (12) 6 (15) 
HPV status Positive 228 (40) 24 (60) 
 Negative 55 (10) 4 (10) 
 Not recorded 279 (50) 12 (30) 
T stage T0 47 (8) 2 (5) 
 T1 101 (18) 9 (23) 
 T2 188 (34) 11 (28) 
 T3 120 (21) 7 (18) 
 T4 106 (19) 11 (28) 
N stage N0 81 (14) 5 (13) 
 N1 61 (11) 3 (8) 
 N2a 42 (8) 3 (8) 
 N2b 274 (49) 22 (55) 
 N2c 99 (18) 7 (18) 
 N3 5 (1) 0 
Stage  I 4 (1) 0 
 
 II 24 (4) 3 (8) 
 III 80 (14) 3 (8) 
 IV 454 (81) 34 (85) 
Use of 
chemotherapy 
ICT 
CRT 
  Cisplatin 
  Cetuximab 
RT only 
38 (7) 
424 (75) 
393 
31 
138 (25) 
1 (3) 
33 (83) 
28 
5 
7 (18) 
 
ICT=induction chemotherapy, CRT=chemoradiotherapy, RT=radiotherapy 
 
 
Table 2: First response assessment PET-CT: summary of response categories (in patients who 
subsequently had second look PET-CT, n=40) 
 
   Lymph node response 
 
 
Primary 
Tumour response 
 Total CR Eq Positive 
Total 40 21 10 9 
CR 13 0 6 7 
Eq 19 14 4 1 
Positive 8 7 0 1 
 
CR=complete response, Eq=equivocal response 
 
Table 3: Second look PET-CT: summary of response categories (n=40) 
   Lymph node response 
 
 
Primary 
Tumour response 
 Total CR Eq Positive 
Total 40 35 1 4 
CR 28 24 1 3 
Eq 5 4 0 1 
Positive 7 7 0 0 
 
CR=complete response, Eq=equivocal response 
 
 
  
 
Table 4: Second-look PET-CT: response categories and disease outcomes 
2nd look PET-
CT result 
Disease +ve Disease -ve PPV/% NPV/% 
 Primary tumour 
CR 1 27 4 96 
Eq 0 5 0 100 
Positive 3 4 43 57 
 Lymph nodes 
CR 0 35 0 100 
Eq 1 2 33 67 
Positive 1 1 50 50 
 
CR=complete response, Eq=equivocal response, PPV=positive predictive value, NPV=negative 
predictive value 
 
 
 
 
 
 
 
 
 
 
	
